Scinovex
article Open AccessTop 1% cited

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

The Lancet · 2010 · Vol. 376(9742) · pp. 687–697
Yung‐Jue BangEric Van CutsemA. FeyereislovaHyun Cheol ChungLin ShenAkira SawakiFlorian LordickAtsushi OhtsuYasushi OmuroTaroh SatohGiuseppe AprileЕ. С. КуликовJulie HillMichaela LehleJosef RüschoffYoon‐Koo Kang
Gastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchGastrointestinal Tumor Research and TreatmentTrastuzumabMedicineInternal medicineCapecitabineChemotherapyRegimenCancerOncologyClinical endpointChemotherapy regimen

MeSH terms

TrastuzumabCapecitabineAdenocarcinomaAgedAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineDrug Therapy, CombinationEsophagogastric JunctionFemaleFluorouracilHumansMale
Citations
7,196
FWCI
237.39
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.